CHAPEL HILL -- Scientists with the Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill have for the first time implicated a growth-promoting cellular protein as one trigger of the inevitable recurrence of advanced prostate cancer in men who are undergoing drug treatment to shut down their sex hormones, or androgens.
The new research may help solve a mystery: why does prostate cancer recur in men treated to get rid of circulating androgens such as testosterone"
Moreover, because chemotherapy after recurrence extends life by only a few months, the new research, "raises the exciting possibility that we can develop a specific drug against this," said senior study co-author Dr. Young Whang, associate professor of medicine at UNC-Chapel Hill.
The study appeared online May 7, 2007, in the Proceedings of the National Academy of Sciences. It is slated for print publication in the journal on May 15.
The protein, named Ack1, is a member of the tyrosine kinase gene family. Ack1 exerts its effect on the reemergence of the cancer by biochemically altering the now inactive androgen receptor in the nucleus of prostate of cells, according to a series of experiments conducted by lead author Dr. Nupam P. Mahajan, assistant professor of pharmacology, and other Lineberger scientists. The kinase activates the receptor via phosphorylation by adding a phosphate group to this protein molecule.
"This biochemical action converts a prostate cell that would need an androgen signal for its growth to one that is independent of the androgen signal," said senior study co-author Dr. Shelton Earp, director of the cancer center, Lineberger professor of cancer research and professor of pharmacology and medicine.
Earp noted that until now scientists havent completely understood what that conversion means. "Our experiments show that this heretofore understudied protein Ack1 may be crucial in at lea
'"/>
Contact: L. H. Lang
llang@med.unc.edu
919-843-9687
University of North Carolina School of Medicine
8-May-2007